Volume 18, Number 1—January 2012
CME ACTIVITY - Research
Accelerating Control of Pertussis in England and Wales
Table 6
Effectiveness of pertussis vaccine among pertussis-infected infants 9 weeks to <6 months of age, England, 2002–2009*
No. doses received before disease onset | No. vaccinated case-patients/total no. (%)† | Average % coverage in comparable population† | % VE (95% CI) |
---|---|---|---|
1 | 174/428 (41) | 64 | 62 (53–69) |
2 | 36/91 (40) | 82 | 85 (77–91) |
3 | 5/24 (21) | 84 | 95 (86–99) |
*Data are for culture-, PCR-, and serology-confirmed cases with onset during 2002–2009. Case-patients received 1 of the following 3 vaccine regimens: 1) DTwP (diphtheria/tetanus/whole-cell pertussis) or DTaP3 (DT/3-component acellular pertussis vaccine) at 2, 3, and 4 mo of age; 2) DTwP at 2, 3, and 4 mo of age; or 3) DTaP5 at 2, 3, and 4 mo of age. VE, vaccine effectiveness.
†Coverage for 1, 2, and 3 doses was calculated by using the number of doses received or 0 doses. Note that case-patients with 0 doses may be counted in >1 group.